. Leading the charge are devices like the Eko smart stethoscope and the Tyto remote otoscope that allow clinicians to remotely auscultate patients’ hearts, lungs and abdomen, and see inside the ear. More devices will surely come, with the aim of replicating the in-office visit.

Before opining on the future of cardiac health, I think it’s important to define what “cardiac health” actually is. If one searches the internet for the term, the result is a cornucopia of self-promotion and advertising. Yes, some of the content is helpful, but mostly these are pitches for an individual’s or group’s services. Not particularly useful, in my opinion.
With the increase of patients experiencing heart failure and clinical challenges to manage advanced heart failure conditions, therapies with implantable devices have become an essential treatment method

The current standard of care for heart failure (HF) is guideline-directed medical therapy combined with device-based interventions in eligible patients. However, many patients experience progressive deterioration in their HF status that warrants additional intervention.

May 4, 2022 – Seeking to bolster its development of a biocompatible graft that promises to reshape the future of cardiac bypass surgery, Medical 21, a medtech device company, recently announced it has filed a Form 1-A with the U.S. Securities and Exchange Commission (SEC) and is now accepting, from the public, reservations for its $40 million funding round on its website.

May 4, 2022 – Single-lead ECG tracings from an Apple Watch interpreted by an artificial intelligence (AI) algorithm developed at

May 4, 2022 — While the COVID-19 pandemic transitions through various phases, nuclear cardiology teams should maintain a flexible approach about which testing protocols to follow in different clinical scenarios as well as how to manage their labs, according to a new information statement issued by the American Society of Nuclear Cardiology (ASNC), International Atomic Energy Agency (

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, celebrates the achievements of the highly skilled electrophysiology team at

May 4, 2022 — CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the FDA 510(k) clearance of the

May 4, 2022 — More than 60 million magnetic resonance imaging (MRI) scans are performed worldwide each year, but imaging for the millions of patients with cardiac implantable electronic devices (CIEDs) such as pacemakers is a logistical challenge, because of concerns with how the magnetic field affects the implants.

May 2, 2022 – Johnson & Johnson MedTech have announced that Biosense Webster, Inc., a worldwide leader in the science and technology of cardiac arrhythmia treatment, enrolled the first patients in its admIRE clinical study in the United States. admIRE is a prospective, multi-center, non-randomized study that will enroll more than 400 patients in the U.S.

May 2, 2022 – A method for delivering genetic material to the body is being tested as a way to repair damaged heart muscle after a heart attack.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now